Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2013

01-09-2013 | Endocrine Tumors

Does Hürthle Cell Carcinoma of the Thyroid Have a Poorer Prognosis than Ordinary Follicular Thyroid Carcinoma?

Authors: Kiminori Sugino, MD, Kaori Kameyama, MD, Koichi Ito, MD, Mitsuji Nagahama, MD, Wataru Kitagawa, MD, Hiroshi Shibuya, MD, Keiko Ohkuwa, MD, Takashi Uruno, MD, Junko Akaishi, MD, Akifumi Suzuki, MD, Chie Masaki, MD, Kunihiko Ito, MD

Published in: Annals of Surgical Oncology | Issue 9/2013

Login to get access

Abstract

Background

Hürthle cell carcinoma (HCC) is a rare form of thyroid carcinoma and is considered an oxyphilic variant of follicular thyroid carcinoma. However, little is known about its biological characteristics or clinical behavior. We conducted a retrospective study to determine whether the prognosis of HCC differs from that of ordinary follicular thyroid carcinoma (OFC).

Methods

The subjects were the 558 patients with follicular thyroid carcinoma who underwent initial surgery at our institution between 1989 and 2010 and consisted of 73 patients with HCC and 485 patients with OFC. There were 410 females and 148 males, and their median age was 51 years. A univariate analysis was conducted in relation to cumulative cause-specific survival (CSS) according to the Kaplan–Meier method for the following variables: age at the time of initial surgery, gender, tumor size, invasiveness, distant metastasis at presentation, and histological type (HCC vs OFC). Differences between groups were analyzed for significance by the log-rank test. Multivariate analysis was performed by using the Cox proportional hazard model.

Results

A total of 4 patients (5.5 %) in the HCC group had distant metastasis compared with 106 patients (21.9 %) in the OFC group. Significant factors in relation to CSS in the univariate analyses were age, tumor size, and invasiveness, but there were no significant differences between the HCC group and the OFC group. Multivariate analysis showed that age, tumor size, and distant metastasis at presentation were significant factors.

Conclusions

HCC does not have a poorer prognosis than OFC.
Literature
1.
DeLellis RA, Lloyd RV, Heitz PU, Eng C. WHO classification of tumours, pathology and genetics of tumours of endocrine organs. Lyon: IARC; 2004:73–6.
2.
Bishop JA, Wu G, Tufano RP, Westra WH. Histological patterns of locoregional recurrence in Hürthle cell carcinoma of the thyroid gland. Thyroid. 2012;22:690–4.PubMedCrossRef
3.
DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH. Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab. 1995;80:2946–53.PubMedCrossRef
4.
Azadian A, Rosen I, Walfish P, Asa SL. Management considerations in Hurthle cell carcinoma. Surgery. 1995;118:711–4.PubMedCrossRef
5.
McDonald MP, Sanders LE, Silverman ML, Chan HS, Buyske J. Hurthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery. 1996;120:1000–4.PubMedCrossRef
6.
Shaha A, Loree T, Shah J. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery. 1995;118:1131–6.PubMedCrossRef
7.
Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J. Follicular Hürthle cell tumors of the thyroid gland. Cancer. 1991;68:1944–53.PubMedCrossRef
8.
Harness JK, Thompson NW, McLeod MK, Eckhauser FE, Lloyd RV. Follicular carcinoma of the thyroid gland: trend and treatment. Surgery. 1984;96:972–80.PubMed
9.
Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic indications for Hürthle cell cancer. World J Surg. 2004;28:1266–70.PubMedCrossRef
10.
Kushchayeva Y, Duh QY, Kebebew E, D’Avanzo A, Clark OH. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg. 2008;195:457–62.PubMedCrossRef
11.
12.
Evans HL, Vassilopoulou-Sellin R. Follicular and Hurthle cell carcinoma of the thyroid: a comparative study. Am J Surg Pathol. 1998;22:1512–20.PubMedCrossRef
13.
Sanders LE, Silverman M. Follicular and Hurthle cell carcinoma: predicting outcome and directing therapy. Surgery. 1998;124:967–74.PubMedCrossRef
14.
Khafif A, Khafif R, Attie J. Hurthle cell carcinoma: a malignancy of low-grade potential. Head Neck. 1999;21:506–11.PubMedCrossRef
15.
Grant CS, Hay ID, Ryan JJ, Bergstralh EJ, Rainwater LM, Goellner JR. Diagnostic and prognostic utility of flow cytometric DNA measurements in follicular thyroid tumors. World J Surg. 1990;14:283–9.PubMedCrossRef
16.
Lang W, Choritz H, Hundeshagen H. Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol. 1986;10:246–55.PubMedCrossRef
17.
Haigh PI, Urbach DR. The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. Surgery. 2005;138:1152–7.PubMedCrossRef
18.
Besic N, Auersperg M, Golouh R. Prognostic factors in follicular carcinoma of the thyroid–a multivariate survival analysis. Eur J Surg Oncol. 1999;25:599–605.PubMedCrossRef
19.
Ito Y, Hirokawa M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, et al. Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination. World J Surg. 2007;31:1417–24.PubMedCrossRef
20.
Sugino K, Ito K, Mimura T, Kameyama K, Iwasaki H, Ito K. Hürthle cell tumor of the thyroid: analysis of 188 cases. World J Surg. 2001;25:1160–3.PubMedCrossRef
21.
Mete O, Asa SL. Oncocytes, oxyphils, Hürthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules. Endocr Pathol. 2010;21:16–24.PubMedCrossRef
22.
Mills SC, Haq M, Smellie WJ, Harmer C. Hürthle cell carcinoma of the thyroid: Retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol. 2009;35:230–4.PubMedCrossRef
23.
24.
Bakiri F, Djemli FK, Mokrane LA, Djidel FK. The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma. Cancer. 1998;82:1146–53.PubMedCrossRef
25.
Paunovic I, Krgovic K, Tatic S, Diklic A, Zivaljevic V, Kalezic N, et al. Surgery for thyroid Hürthle cell tumours—a single institution experience. Eur J Surg Oncol. 2006;32:458–61.PubMedCrossRef
26.
Chen H, Nicol TL, Zeiger MA, Dooley WC, Ladenson PW, Cooper DS, et al. Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg. 1998;227:542–6.PubMedCrossRef
27.
Wasvary H, Czako P, Poulik J, Lucas R. Unilateral lobectomy for Hurthle cell adenoma. Am Surg. 1998;64:729–32.PubMed
28.
Stojadinovic A, Hoos A, Ghossein RA, Urist MJ, Leung DH, Spiro RH, et al. Hürthle cell carcinoma: a 60-year experience. Ann Surg Oncol. 2002;9:197–203.PubMed
29.
Bhattacharyya N. Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg. 2003;129:207–10.PubMedCrossRef
30.
Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, et al. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer. 2003;97:1186–94.PubMedCrossRef
31.
Sugino K, Kameyama K, Ito K, Nagahama M, Kitagawa W, Shibuya H, et al. Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma. Thyroid. 2012;22:798–804.PubMedCrossRef
32.
Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, et al. Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid. 2011;21:751–7.PubMedCrossRef
Metadata
Title
Does Hürthle Cell Carcinoma of the Thyroid Have a Poorer Prognosis than Ordinary Follicular Thyroid Carcinoma?
Authors
Kiminori Sugino, MD
Kaori Kameyama, MD
Koichi Ito, MD
Mitsuji Nagahama, MD
Wataru Kitagawa, MD
Hiroshi Shibuya, MD
Keiko Ohkuwa, MD
Takashi Uruno, MD
Junko Akaishi, MD
Akifumi Suzuki, MD
Chie Masaki, MD
Kunihiko Ito, MD
Publication date
01-09-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 9/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2965-y

Other articles of this Issue 9/2013

Annals of Surgical Oncology 9/2013 Go to the issue

Colorectal Cancer

Modern Rectal Cancer Multidisciplinary Treatment: The Role of Radiation and Surgery

Gastrointestinal Oncology

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Asian Patients: 100 Consecutive Patients in a Single Institution

Head and Neck Oncology

Outcomes and Prognostic Factors of Post-irradiation and de novo Sarcomas of the Head and Neck: A Histologically Matched Case-Control Study

Pancreatic Tumors

Posterior Approach for Laparoscopic Pancreaticoduodenectomy to Prevent Replaced Hepatic Artery Injury

Hepatobiliary Tumors

Hepatic Artery Infusion: Still an Option?

Endocrine Tumors

Should an Involved but Functioning Recurrent Laryngeal Nerve be Shaved or Resected in a Locally Advanced Papillary Thyroid Carcinoma?